ADVERTISEMENT

For Acute Lymphoblastic Leukemia Patients, New Hope from an Old Treatment

New research has shown that high-dose methotrexate improved five-year event-free survival for ALL patients with no significant differences in toxicities.

$author$
PUBLISHED MONDAY, JUNE 13, 2011
Talk about this article with other patients, caregivers, and advocates in the Leukemia CURE discussion group.
More than 50 years ago, renowned cancer researcher Sidney Farber, MD, began using methotrexate to treat children and young adults with acute lymphoblastic leukemia (ALL), a disease that was almost always fatal. Methotrexate inhibits leukemia cell proliferation by blocking its ability to use folate, an essential vitamin. Today, with methotrexate used in various combinations and dosages, survival rates are above 80 percent.

ALL begins in the bone marrow and spreads rapidly. For the last two decades, ALL patients were treated with methotrexate and asparaginase (known as the Capizzi regimen), starting with a low dose of methotrexate that was gradually increased as patients grew more tolerant. Capizzi successfully prevented relapses of ALL in the bone marrow. Yet relapses of the disease occurred, particularly in the central nervous system, prompting scientists to search for more effective regimens.

New research has shown that high-dose methotrexate—50 times higher than the initial dose in standard treatment—improved five-year event-free survival with no significant differences in toxicities.

In a randomized phase 3 study of 2,426 patients with high-risk B-precursor ALL, researchers showed that a high dose of methotrexate, accompanied by leucovorin to help control side effects, was "clearly superior to the standard treatment," according to Eric Larsen, MD, of Maine Medical Center in Portland, Me. In fact, the researchers stopped enrolling new patients and encouraged eligible patients to switch to the new regimen after a planned interim analysis showed that those receiving high doses had a five-year event-free survival of 82 percent compared with 75.4 percent for the Capizzi regimen.

Larson added that the researchers were surprised to learn that patients in the high-dose arm also had lower rates of febrile neutropenia: 5.2 percent compared with 8.2 percent in the Capizzi arm.

Talk about this article with other patients, caregivers, and advocates in the Leukemia CURE discussion group.
ADVERTISEMENT
Related Articles
CPX-351 Receives Fast Track Designation for Relapsed AML
BY JASON M. BRODERICK
The Food and Drug Administration granted a Fast Track Designation to CPX-351 for the treatment of elderly patients with relapsed acute myeloid leukemia (AML).
FDA Updates Gazyva Label for Frontline Chronic Lymphocytic Leukemia
BY SILAS INMAN
The FDA has updated the label for Gazyva (obinutuzumab) plus chlorambucil to include data from stage 2 of the phase 3 CLL11 study, which detailed an improvement in progression-free survival as a frontline treatment for patients with chronic lymphocytic leukemia.
Blincyto Approved for Acute Lymphoblastic Leukemia
BY SILAS INMAN
The FDA approved the anti-CD19 immunotherapy Blincyto (blinatumomab) as a treatment for Philadelphia chromosome-negative acute lymphoblastic leukemia.
Under the Microscope: Cancer Biomarkers
BY JEANNE ERDMANN
When deciding on a cancer treatment—and determining its effectiveness—look for a biomarker.
Related Videos
Dr. Stuart Goldberg Answers Common Questions from CML Patients
Stuart Goldberg, hematologist/oncologist at John Theurer Cancer Center, discusses some of the common questions he gets from his patients with chronic myeloid leukemia.
Recent Publications
  • photo
    photo
    photo
    photo
    photo
  • photo
    photo
    photo
    photo
    photo
ADVERTISEMENT
$auto_registration$